Alexion Pharm Inc (ALXN) |
|
153.84 -0.65 (-0.42%)
|
02-25 11:44 |
|
Open: |
155.23 |
Pre. Close: |
154.49 |
|
High:
|
155.48 |
Low:
|
153.84 |
|
Volume:
|
448,439 |
Market Cap:
|
33,821M |
|
|
|
|
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
155.163 - 156.1 |
156.1 - 156.998 |
|
Low:
|
150.83 - 151.94 |
151.94 - 153.003 |
|
Close:
|
152.791 - 154.424 |
154.424 - 155.989 |
|
Technical analysis |
as of: 2021-02-25 11:07:47 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 185.48 One year: 189.92 |
| Support: |
Support1: 152.65 Support2: 127.00 |
| Resistance: |
Resistance1: 158.80 Resistance2: 162.60 |
| Pivot: |
155.36  |
| Moving Average: |
MA(5): 154.44 MA(20): 155.31
MA(100): 138.94  MA(250): 117.98 |
| MACD: |
MACD(12,26): 0.25 Signal(9): 0.75 |
| Stochastic oscillator: |
%K(14,3): 22.22 %D(3): 22.12 |
| RSI: |
RSI(14): 48.80 |
| 52-week: |
High: 162.60 Low: 72.67 Change(%): 64.3 |
| Average Vol(K): |
3-Month: 307651 10-Days: 212994 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.ALXN has closed above bottom band by 34.5%. Bollinger Bands are 67.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to ALXN's normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Mon, 22 Feb 2021
How Many Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Do Institutions Own? - Yahoo Finance
Mon, 22 Feb 2021
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals - Business Wire
Tue, 16 Feb 2021
Valuation: Alexion Pharmaceuticals (ALXN) Stock Looks Attractive. $215.0 Trefis Price (36% Upside). [2/16/2021] - Trefis
Fri, 12 Feb 2021
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Expected to Post Quarterly Sales of $1.57 Billion - MarketBeat
Thu, 11 Feb 2021
ALXN vs. BMRN: Which Stock Is the Better Value Option? - Yahoo Finance
Thu, 04 Feb 2021
Alexion Pharmaceuticals EPS beats by $0.40, beats on revenue - Seeking Alpha
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
219 |
| Shares Float (M) |
218 |
|
% Held by Insiders
|
0.28 |
|
% Held by Institutions
|
93.36 |
|
Shares Short (K)
|
3,870 |
|
Shares Short P. Month (K)
|
3,530 |
Stock Financials |
|
EPS
|
4.310 |
|
EPS Est This Year
|
5.620 |
|
EPS Est Next Year
|
7.130 |
|
Book Value (p.s.)
|
50.570 |
|
Profit Margin
|
16.32 |
|
Operating Margin
|
47.42 |
|
Return on Assets (ttm)
|
10.7 |
|
Return on Equity (ttm)
|
8.9 |
|
Qtrly Rev. Growth
|
25.8 |
|
Gross Profit (p.s.)
|
21.031 |
|
Sales Per Share
|
26.792 |
|
EBITDA (p.s.)
|
14.173 |
|
Qtrly Earnings Growth
|
23.60 |
|
Operating Cash Flow (M)
|
2,680 |
|
Levered Free Cash Flow (M)
|
1,790 |
Stock Valuations |
|
PE Ratio
|
35.84 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.05 |
|
Price to Sales
|
5.76 |
|
Price to Cash Flow
|
12.61 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
